Login to Your Account



Pulmocide Attracts $27.5M Series A for Respiratory Infections

By Nuala Moran
Staff Writer

Monday, November 25, 2013
LONDON – Pulmocide Ltd. has raised £17 million (US$27.5 million) in Series A funding to embark on the discovery of a new generation of inhaled treatments for serious viral and fungal infections of the respiratory tract. If that is a large amount of money for the first round of a biotech company with no compounds, the reason lies in the expertise and track record of the founders, who are both former Glaxosmithkline plc executives.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription